Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent

Volume:10   Issue:4
Pp: 368-383
L. Tentori, A. Muzi, A.S. Dorio, M. Scarsella, C. Leonetti, G.M. Shah, W. Xu, E. Camaioni, B. Gold, R. Pellicciari, F. Dantzer, J. Zhang and G. Graziani
DOI: 10.2174/156800910791208571

Order Reprints Order Eprints

Targeting CREB for Cancer Therapy: Friend or Foe

Volume:10   Issue:4
Pp: 384-391
X. Xiao, B.X. Li, B. Mitton, A. Ikeda and K.M. Sakamoto
DOI: 10.2174/156800910791208535

Order Reprints Order Eprints

Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer

Volume:10   Issue:4
Pp: 392-401
B. Wegiel, S. Evans, R. Hellsten, L.E. Otterbein, A. Bjartell and J.L. Persson
DOI: 10.2174/156800910791208562

Order Reprints Order Eprints

Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy

Volume:10   Issue:4
Pp: 411-421
S. Cruet-Hennequart, A.M. Prendergast, F.P. Barry and M.P. Carty
DOI: 10.2174/156800910791208553

Order Reprints Order Eprints

Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells

Volume:10   Issue:4
Pp: 422-431
S. Carloni, F. Fabbri, G. Brigliadori, P. Ulivi, R. Silvestrini, D. Amadori and W. Zoli
DOI: 10.2174/156800910791208580

Order Reprints Order Eprints